

CORRECTION

Open Access



# Correction to: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

Therese Sjöholm<sup>1\*†</sup>, Alexander Korenyushkin<sup>2†</sup>, Gustav Gammelgård<sup>3</sup>, Tina Sarén<sup>3</sup>, Tanja Lövgren<sup>3</sup>, Angelica Loskog<sup>3</sup>, Magnus Essand<sup>3</sup>, Joel Kullberg<sup>1,2</sup>, Gunilla Enblad<sup>3†</sup> and Håkan Ahlström<sup>1,2†</sup>

**Correction to:** *Cancer Imaging* 22 , 76 (2022).

<https://doi.org/10.1186/s40644-022-00513-y>

During the publication process of the original article the arrows of Fig. 1 were misplaced. The correct figure is available in this correction article, the original article has been updated.

---

<sup>†</sup>Therese Sjöholm and Alexander Korenyushkin contributed equally as first authors.

---

<sup>†</sup>Gunilla Enblad and Håkan Ahlström contributed equally as senior authors.

---

The online version of the original article can be found at <https://doi.org/10.1186/s40644-022-00513-y>.

---

\*Correspondence:

Therese Sjöholm  
therese.sjoholm@surgsci.uu.se


<sup>1</sup>Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

<sup>2</sup>Antaros Medical AB, Mölndal, Sweden

<sup>3</sup>Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 1** Example patient scanned over an extended period of time. Maximum Intensity Projection (MIP) SUV images (**a, b**), axial b900 DW images (**c, d**) and line graphs of tumor  $SUV_{max}$  and  $ADC_{mean}$  quantification over time (**e, f**). Pre-therapy ( $t_0$ ) and early post-therapy ( $t_1$ ) images are shown in inverted grey scale. A large decrease in MTV between the pre-therapy (MTV = 337 ml) and early post-therapy (MTV = 19 ml) scans was measured, as visualized by the MIP SUV images (**a, b**). Although this patient had a large total tumor burden pre-therapy, the OS was long (48.2 months with last follow-up as endpoint).  $SUV_{max}$  and  $ADC_{mean}$  tumor quantification over time (**e, f**), indicate an intra-tumor heterogenic response to the CAR T-cell therapy. Target lesion

Published online: 19 May 2023

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.